Enara Health Review

Enara Health — Provider Profile

April 2026 context: This provider is active. Orforglipron (Eli Lilly oral GLP-1) is not yet FDA-approved — PDUFA date April 10, 2026. Medicare GLP-1 Bridge coverage for obesity is pending. Compounded semaglutide supply is declining under FDA enforcement pressure.

Overview

Enara Health is a physician-led obesity medicine practice built around an insurance-first model. Where most telehealth GLP-1 providers previously defaulted to cash-pay with compounded medications, the compounding collapse has fully validated Enara's approach — the market has consolidated around branded medications, exactly where Enara has always operated. They accept major commercial insurance plans and focus on getting brand-name GLP-1s covered through aggressive prior authorization and appeals. The clinical program is comprehensive: board-certified obesity medicine physicians, registered dietitians, behavioral health counselors, and lab work are all included. If your insurance covers it, Enara delivers a Calibrate-level program at a fraction of the out-of-pocket cost. For patients without GLP-1 insurance coverage, Enara now prescribes orforglipron ($149/mo through the manufacturer) as a branded oral alternative — closing what was previously their biggest gap.

Medications Offered

• Brand Wegovy (semaglutide) — FDA-approved; prescribed through insurance with prior authorization handling. Now includes Wegovy HD (7.2mg dose, not yet FDA-approved as of April 2026) for patients who need maximum efficacy (20.7% weight loss in trials)
• Brand Zepbound (tirzepatide) — Dual GIP/GLP-1 receptor agonist; prior auth and insurance appeals included
• Orforglipron (oral GLP-1) — Awaiting FDA approval (PDUFA April 10, 2026); announced at $149/mo through the manufacturer. Daily oral pill, no injections. Expected as a branded budget option for patients without injectable GLP-1 insurance coverage
• Non-GLP-1 medications — Other evidence-based obesity medications as clinically appropriate
• No compounded GLP-1s — Enara has never offered compounded medications, a position that has aged well given the 2026 FDA enforcement campaign

The anticipated addition of orforglipron is significant. Enara's previous biggest limitation was the lack of any affordable option for patients whose insurance denied GLP-1 coverage. At $149/month announced for an FDA-approved oral medication (pending April 10, 2026 PDUFA), orforglipron would give Enara a credible answer for those patients — still branded, still within Enara's insurance-aligned philosophy, but accessible without prior authorization approval.

Pricing

Enara's pricing still makes the most sense through the lens of insurance. For patients with commercial plans that cover obesity medicine visits, the $0-$99/month program fee is dramatically lower than FORM Health's $199/month or Calibrate's subscription. The anticipated change in 2026: patients who can't get injectable GLP-1 insurance coverage are expected to have orforglipron at $149/month as a branded alternative pending FDA approval, which would close Enara's previous cash-pay gap. Medicare patients will also have a new pathway through the Medicare Bridge Program at $50/month copay starting July 2026.

States Served

Available in 42+ states as of early 2026, up from 38 states in early 2026. Not yet fully nationwide. Check Enara Health's website for current state availability before beginning the intake process.

Insurance

• Clinical visits: Enara accepts most major commercial insurance plans. Many patients pay $0 out-of-pocket for physician and dietitian visits depending on plan structure.
• Medication: Brand-name GLP-1s only (Wegovy, Zepbound), prescribed through insurance. Enara handles prior authorizations and appeals aggressively — this is a core part of their value proposition.
• Orforglipron as cash-pay alternative: If your insurance denies injectable GLP-1 coverage and appeals are exhausted, Enara expects to prescribe orforglipron ($149/mo announced) as an FDA-approved oral option once approved (PDUFA April 10, 2026). This would significantly reduce what was previously the biggest limitation of the insurance-first model.
• Medicare Bridge Program: Medicare patients can access GLP-1s at $50/month copay through the federal Medicare Bridge Program (expected 2026, pending). Enara assists with enrollment.

Consultation Process

Model: Video consultations (telehealth-only) with board-certified obesity medicine physicians, registered dietitians, and behavioral health counselors.

1. Insurance verification — Enara's team verifies your coverage and confirms expected costs before you begin (this step takes longer than cash-pay platforms)
2. Comprehensive intake including medical history, metabolic health assessment, eating patterns, physical activity, behavioral health screening, and identification of comorbidities
3. Comprehensive metabolic panel — lab work ordered at intake to establish metabolic baseline
4. Initial video visit with a board-certified obesity medicine physician — thorough medical evaluation and treatment planning
5. Personalized treatment plan covering medication, dietary modifications (with registered dietitian), behavioral strategies (with behavioral health counselor), and exercise programming
6. Prior authorization submitted for brand-name GLP-1 medication if indicated — Enara handles the paperwork and appeals
7. 1-year structured program with regular video follow-ups, quarterly lab reviews, and ongoing dietitian and behavioral health support

Pros

• Insurance-first model — potentially $0 out-of-pocket for clinical visits, dramatically cheaper than cash-pay programs
• Board-certified obesity medicine physicians — same specialist standard as FORM Health
• Registered dietitian included in program — nutrition counseling at no additional cost
• Behavioral health counselor access included — addresses psychological dimensions of weight management
• Lab work included — comprehensive metabolic panels at intake and quarterly follow-up
• Aggressive prior authorization and insurance appeals handling — Enara fights for brand-name GLP-1 coverage
• 1-year structured program with quarterly lab reviews — genuine longitudinal care, not just prescription refills

Cons

• Insurance-dependent — without commercial insurance that covers obesity medicine, Enara's program fee advantage disappears (though orforglipron at $149/mo is expected to provide a medication fallback once FDA-approved — PDUFA April 10, 2026)
• No compounded GLP-1 option — though this is now irrelevant as compounded supply is effectively at risk under FDA enforcement
• Available in 42+ states — expanded from 38 in 2026, but still not fully nationwide
• Longer intake process — insurance verification adds time before treatment can begin
• Smaller operation with less brand recognition than FORM Health, Calibrate, or Ro
• Less flexibility for cash-pay patients — the insurance-first model is the only model
• If your insurer won't cover GLP-1s, Enara's prior auth expertise may not be enough

Best For

Patients with commercial insurance that covers obesity medicine visits and has a reasonable path to brand-name GLP-1 coverage. Enara is especially strong for patients who want comprehensive, specialist-level care — physician, dietitian, behavioral health, lab work — but can't justify $199-$300/month in cash-pay program fees. If your insurance cooperates, Enara delivers one of the most complete obesity medicine programs available in telehealth at the lowest out-of-pocket cost we've seen. Also a strong fit for patients who've been denied GLP-1 coverage elsewhere and need a team that knows how to navigate prior authorizations and appeals.

Editorial Verdict

Enara Health occupies a unique position in the telehealth GLP-1 landscape: it's the only provider we've reviewed that builds its entire model around insurance rather than treating insurance as a nice-to-have. The clinical program — board-certified obesity medicine physicians, registered dietitians, behavioral health counselors, comprehensive lab work, and a structured 1-year program — rivals or exceeds what larger, better-known platforms like FORM Health and Calibrate offer. And for patients with good insurance, it can cost a fraction of what those programs charge out-of-pocket.

The catch is less severe than it used to be. Enara's model still lives and dies by your insurance coverage for maximum value, but orforglipron ($149/mo announced — pending FDA approval, PDUFA April 10, 2026) means patients whose insurance denies injectable GLP-1s have a well-established branded oral alternative. That eliminates the previous binary outcome where insurance denial meant Enara had nothing to offer. The post-compounding market has shifted decisively in Enara's favor: with compounded supply effectively at risk under FDA enforcement and competitors like Hims moving to brand-only at $249-$299/month, Enara's insurance-first approach and prior authorization expertise look prescient rather than limiting. CagriSema (semaglutide + cagrilintide), still pending FDA approval, could further expand the branded medication menu available through insurance.

Enara is a smaller company with less brand recognition than the names you see in paid ads. That doesn't reflect clinical quality — it reflects marketing budgets. The physician credentials, multidisciplinary team, and structured program are as rigorous as anything in the space. The question isn't whether Enara is good. The question is whether your insurance makes it accessible.

Related Content

• Starting GLP-1 in 2026 — Updated guide for new patients
• Best Oral GLP-1 Options 2026 — Orforglipron and oral Wegovy compared
• Medicare GLP-1 Coverage Guide — Medicare Bridge Program details
• Best GLP-1 Weight Loss Programs 2026 — All providers ranked
• GLP-1 Pricing Breakdown by Provider — Side-by-side cost comparison
• GLP-1 Side Effects & Safety FAQ — Managing common side effects
• How to Switch GLP-1 Providers — Step-by-step switching guide